TY - JOUR T1 - Rethinking of doxycycline therapy in Creutzfeldt-Jakob disease JF - Journal of Neurology, Neurosurgery & Psychiatry JO - J Neurol Neurosurg Psychiatry SP - 705 LP - 705 DO - 10.1136/jnnp-2014-310127 VL - 86 IS - 7 AU - Maurizio Pocchiari AU - Anna Ladogana Y1 - 2015/07/01 UR - http://jnnp.bmj.com/content/86/7/705.abstract N2 - Compassionate use of doxycycline, a tetracycline antibiotic, in patients with Creutzfeldt-Jakob disease (CJD) revealed an increased survival of 4–7 months as compared with historical controls, a result not confirmed by a randomised, double blind, placebo-controlled trial.1 Is then therapy with doxycycline for patients with CJD over? The report of Assar et al2 on a single patient with variably protease-sensitive prionopathy (VPSPr),3 a rare subtype form of sporadic CJD, who received 4-year treatment with doxycycline at a relatively early stage of disease, suggests it is not and encourages novel studies on the use of doxycycline in prion diseases. The patient, who carried the commonly VPSPr-associated valine homozygosity … ER -